Pharmcokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 5, 2003, Pages 191-197

  Shin, Beom S ^a   Kim, Dong H ^a   Cho, Chang Y ^a   Park, Si K ^b   Chung, Sun G ^b   Cho, Eui H ^b   Lee, Sun H ^b   Joo, Jeong H ^b   Kwon, Ho S ^b   Lee, Kang C ^a   Yoo, Sun D ^a  

^a Sungkyunkwan University   (South Korea)

^b Samil Pharmaceutical Co Ltd   (South Korea)

Author keywords

Allometry; Antineoplastic; SJ 8029; Species invariant time

Indexed keywords

4 (3,5 DIMETHYLPHENYL)PIPERAZIN 1 CARBOXYLIC ACID [5 [1 [3 (ACRIDIN 9 YLAMINO) 5 HYDROXYMETHYLPHENYLCARBAMOYL]ETHYLCARBAMOYL] 6 ETHYL 2 METHOXYPYRIDIN 3 YL]AMIDE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; SJ 8029; UNCLASSIFIED DRUG; 4 (3,5 DIMETHYLPHENYL)PIPERAZINE 1 CARBOXYLIC ACID(5 (1 (3 (ACRIDINE 9 YL AMINO) 5 HYDROXYMETHYLPHENYLCARBAMOYL) ETHYLCARBAMOYL) 6 ETHYL 2 METHOXYPYRIDINE 3 YL)AMIDE; 4-(3,5-DIMETHYLPHENYL)PIPERAZINE-1-CARBOXYLIC ACID(5-(1-(3-(ACRIDINE-9-YL-AMINO)-5-HYDROXYMETHYLPHENYLCARBAMOYL)-ETHYLCARBAMOYL)-6-ETHYL-2-METHOXYPYRIDINE-3-YL)AMIDE; ACRIDINE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ALLOMETRY; ANALYSIS OF VARIANCE; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME INHIBITION; MALE; MATHEMATICAL COMPUTING; MICROTUBULE; MOUSE; NONHUMAN; RABBIT; RAT; TIME; ANIMAL; AREA UNDER THE CURVE; BLOOD; BODY WEIGHT; DRUG ANTAGONISM; DRUG EFFECT; HALF LIFE TIME; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PREDICTION AND FORECASTING; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY WEIGHT; DNA TOPOISOMERASES, TYPE II; DOGS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED ICR; MICROTUBULES; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PYRIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 0041663524     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.352     Document Type: Article

References (12)

1. Cho EH, Chung SG, Lee SH, et al. 9-Aminoacridine derivatives and process for the preparation thereof. PCT/KR02/00392, March 3, 2002.
2. Van Hille B, Hill BT. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II. A potent tool for identification and characterization of topoisomerase II-targeting antitumor agents. Cancer Chemother Pharmacol 1998; 42: 345-356.
3. Finlay GJ, Holdaway KM, Baguley BC. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation. Oncol Res 1994; 6: 33-37.
4. Corbett AH, Hong D, Osheroff N. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. J Biol Chem 1993; 268: 14394-14398.
5. Cho CY, Shin BS, Kim DH, et al. Analysis and stability of a novel anticancer agent, SJ-8029, possessing microtubule and topoisomerase inhibiting activities. Anal Lett 2002; 35: 2133-2143.
6. Sacher G. In CIBA Foundation Colloquia on Aging, Wolstenholme GEW, O'Connor M (eds). Churchill: London, 1959; 115-133.
7. Dedrick RL. Animal scale-up. J Pharmacokin Biopharm 1973; 1: 435-461.
8. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245: R768-R775.
9. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15: 1071-1121.
10. Ings RMJ. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 1990; 20: 1201-1231.
11. McNamara PJ. Interspecies scaling in pharmacokinetics. In Pharmaceutical Bioequivalence, Welling PG, Tse FLS, Dighe SV (eds). Marcel Dekker: New York, 1991; 267-300.
12. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.